The European Medicines Agency (EMA) has validated the marketing authorisation application (MAA) submitted by Soleno ...

Tevimbra is currently approved in the EU as a treatment for gastric cancer, esophageal squamous cell cancer and small cell ...

AstraZeneca (AZN) stock in focus as its antibody drug Imfinzi gains EU panel support for treating muscle-invasive bladder ...

The two active substances are antivirals that inhibit HIV reverse transcriptase through incorporation into the viral DNA, ...

The antibiotic can no longer be used in moderate acne vulgaris, eradication of Helicobacter pylori, and prevention of ...

Autolus' CAR-T cell therapy for a rare and aggressive form of acute lymphoblastic leukaemia (ALL), Aucatzyl, has been ...

USD/JPY struggles to break above the 20-day Exponential Moving Average (EMA), which is currently around 144.45, indicating ...

The European Medicines Agency (EMA) has designated allopurinol as the first orphan drug for the treatment of Marfan syndrome, ...

EMA grants conditional marketing authorization to Autolus’ Aucatzyl to treat adults with acute lymphoblastic leukaemia: Amsterdam, The Netherlands Monday, May 26, 2025, 16:00 Hr ...

Company continues to advance QRX003 in late-stage clinical trials in Netherton Syndrome patients Regulatory milestone ...

NZD/USD is trading around 0.5960 during the European hours on Thursday. The pair has trimmed its daily losses as a market ...

EMA committee recommends marketing approval for SpringWorks’ mirdametinib to treat adult & paediatric patients with NF1-PN: Stamford, Connecticut Tuesday, May 27, 2025, 12:00 Hr ...